A case–control study of 40 participants, published in May 2023 in JAMA Psychiatry, demonstrated that translocator protein total distribution (TSPO VT), which is a marker for gliosis, is elevated in multiple regions of the brain in patients experiencing persistent depressive (low energy, slowed motor speech, anhedonia) and cognitive symptoms associated with COVID-19 illness, compared to controls with COVID-19 but no persistent symptoms (23). The gene discussed is TSPO; the disease is COVID-19.